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Graves’ disease (GD) involves the presence of agonistic auto-antibodies against the
thyrotropin receptor (TSHR), which are responsible for the clinical symptoms. While
failure of TSHR tolerance is central to GD pathogenesis, the process leading to this
failure remains poorly understood. Two mechanisms intimately linked to tolerance have
been proposed to explain the association of SNPs located in TSHR intron 1 to GD:
(1) differential alternative splicing in the thyroid; and (2) modulation of expression in
the thymus. To elucidate the relative contribution to these two mechanisms to GD
pathogenesis, we analyzed the level of full-length and ST4 and ST5 isoform expression in
the thyroid (n = 49) and thymus (n = 39) glands, and the influence of intron 1-associated
SNPs on such expression. The results show that: (1) the level of flTSHR and ST4
expression in the thymus was unexpectedly high (20% that of the thyroid); (2) while
flTSHR is the predominant isoform, the levels are similar to ST4 (ratio flTSHR/ST4 = 1.34
in the thyroid and ratio flTSHR/ST4 in the thymus= 1.93); (3) next-generation sequencing
confirmed the effect of the TSHR intron 1 polymorphism on TSHR expression in the
thymus with a bias of 1.5 ± 0.2 overexpression of the protective allele in the thymus
compared to the thyroid; (4) GD-associated intron 1 SNPs did not influence TSHR
alternative splicing of ST4 and ST5 in the thyroid and thymus; and (5) three-color confocal
imaging showed that TSHR is associated with both thymocytes, macrophages, and
dendritic cells in the thymus. Our findings confirm the effect of intron 1 polymorphisms
on thymic TSHR expression and we present evidence against an effect on the relative
expression of isoforms. The high level of ST4 expression in the thymus and its distribution
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within the tissue suggest that this would most likely be the isoform that induces central
tolerance to TSHR thus omitting most of the hinge and transmembrane portion. The lack
of central tolerance to a large portion of TSHR may explain the relatively high frequency
of autoimmunity related to TSHR and its clinical consequence, GD.
Keywords: Graves’ disease, TSHR, tolerance, splicing isoforms, thymus, thyroid, next-generation sequencing
INTRODUCTION
Graves’ disease (GD) is a highly prevalent autoimmune disease
characterized by the presence of agonistic auto-antibodies against
the thyrotropin receptor (TSHR), which are responsible for
hyperthyroidism and extrathyroidal manifestations (1, 2). Failure
of tolerance to the TSHR is central to the pathogenesis of GD;
however, our understanding of the process that leads to this
failure remains incomplete.
The strong contribution of genetic factors to GD is best
demonstrated in twin concordance studies that suggest that
as much as 79% of the risk of developing GD is hereditary
(3). During the past 25 years, classical genetic approaches and
more recently, genome-wide association studies (GWAS), have
identified several gene loci whose polymorphismsmay contribute
to GD susceptibility. Among the confirmed genes in the HLA
region, CTLA4 and PTPN22 confer a higher risk; however,
individual contributions, with the exception of HLA, are limited
(4–6). The products of these genes participate in the regulation
of the immune response and have been implicated in other
autoimmune diseases but do not explain why the autoimmune
response focuses on the thyroid gland. Common polymorphisms
have also been found in the genes specifically expressed in the
thyroid [e.g., the thyrotropin receptor [TSHR] or thyroglobulin
[TG] (7, 8)]; however, only the association with TSHR has been
repeatedly confirmed [reviewed in (4, 5, 9, 10)]. Since the loss of
tolerance to TSHR is the central mechanism for GDpathogenesis,
there is a great interest in understanding how these TSHR
polymorphisms contribute to the failure of tolerance.
TSHR consists of 10 exons encoding a 764 amino acid protein
of ∼95 kDa that is converted to a 120 kDa protein following
substantial glycosylation (11). The original TSHR peptide chain
undergoes proteolytic cleavage, generating two subunits: (1)
the A-subunit, encoded by exons 1–9, which constitutes the
extracellular domain; and (2) the B-subunit, encoded by exon
10, which consists of a transmembrane region plus a 5 kDa C
connecting peptide (12). Following the excision of the C peptide,
the A- and B-subunits remain linked by disulfide bridges that
can be subsequently reduced, and the A-subunit is partially
shed, whereas B-subunit will remain anchored to the membrane
(13, 14). Controversy remains regarding the persistence of single
chain (uncleaved) TSHR on the surface of thyrocytes and to what
extent subunit A is physiologically shed (15, 16).
The TSHR gene is expressed at medium to low levels in the
thyroid (207 copies per million transcripts) and is extremely
low in all other tissues (data from the GTEX portal, <0.3
transcripts per million in subcutaneous fat or 0.5 in the brain),
except for AIRE-expressing orbital fibrocytes from GD patients
with ophthalmic pathologies (17). As a reference, the classical
housekeeping gene, GAPDH, has 813 transcripts per million in
the thyroid.
In addition to the full-length TSHR (flTSHR), five truncated
TSHR transcripts have been reported in multiple studies, of
which ST4 (1.3 kb) and ST5 (1.7 kb) are themost highly expressed
(18–20). ST4 and ST5 share the first eight exons with the flTSHR
but contain an additional ninth exon that is unique and different
in ST4 and ST5, both of which lack exon 10. These unique
exons are encoded in two different regions of intron 8, which
are selected and retained in the mRNA of the corresponding
alternatively spliced forms. If translated, both ST4 and ST5
would encode most of the leucine-rich repeats containing the
TSH-binding extracellular region, but neither the hinge nor the
transmembrane domain of the TSHR; therefore, is plausible that
they are secreted (Figure 1).
Different studies have demonstrated a significant association
between SNPs in the 40 kb region in the 5′ side of the large
intron 1 (106 kb) of TSHR with GD [reviewed in (5)] (Figure 1).
Two different but not mutually exclusive mechanisms have been
postulated to explain this association. Brand et al. proposed
that these SNPs influence mRNA splicing, which results in
increased levels of the ST4 and ST5 transcripts encoding the short
isoforms (21). The authors proposed that the short ST4 and ST5
variants would be translated into the putatively soluble TSHR
forms, released into the circulation where they become available
to antigen presenting cells in the periphery, where they may
contribute to inducing an autoimmune response to the TSHR.
However, it is unclear why these isoforms are immunogenic,
rather than tolerogenic or ignored, in this hypothesis. In one
experimental model, the soluble TSHR A subunit is more
immunogenic than the membrane-bound TSHR (22); however,
ST4 and ST5 differ from Subunit A in one exon and is difficult to
predict their immunogenicity. Therefore, Brand et al. postulate
the failure in peripheral tolerance as the crucial checkpoint for
the development of GD.
The second proposed mechanism is based on our finding
that the GD-associated SNPs in the intron 1 alleles modulate
TSHR expression in the thymus. By measuring the levels of
allele-specific TSHR mRNA in the thymus, we demonstrated
that individuals carrying the protective genotype have higher
levels of thymic TSHR mRNA compared to those with the
disease-predisposing genotype. According to the well-established
mechanisms of central tolerance, the expression of self-antigens
in the thymus is required to develop a tolerant T cell repertoire
(23, 24); a dose response relationship between the amount of
a self-antigen in the thymus, and the frequency of T cells
clones that can recognize it in the periphery, which has been
Frontiers in Immunology | www.frontiersin.org 2 July 2019 | Volume 10 | Article 1695
Marín-Sánchez et al. TSHR Isoforms and Tolerance
FIGURE 1 | TSHR gene, GD-associated intron 1 polymorphisms and the predicted proteins expressed as cell-anchored proteins and as soluble forms. This figure
shows the unique structure of TSHR. Intron 1 contains the GD-associated SNPs scattered on a region of ∼30 kb at the 5′ end of intron 1. The numbers on top of the
gene diagram correspond to the amino acids coded by each exon. The numbers on the bottom of the gene are the distances in kilobases (Kb). The primary
associated SNPs are labeled in addition to the area of histone 3 lysine 4 monomethylated (H3K4me1), where the repressor factor, PLZF, was found to bind, reducing
TSHR transcription. The exons used exclusively by the ST4 and ST5 isoforms are labeled in green and blue, respectively. The TSH holoreceptor (TSHR) and the two
short isoforms (ST4 and ST5) are depicted, showing that the short isoforms contained less than half of the potential immunogenic regions of the receptor, including a
large proportion of the extracellular domain, specially the hinge. C, C peptide; SP, signal peptide; LRR, Leucine Reach Repeats; TMD, transmembrane domain; CM,
Cytoplasmic Motifs [This figure is based on Figure 1 and Figure 2 of manuscript (9). Reproduced with permission of Thieme editorial].
demonstrated for the insulin gene in type 1 diabetes (25, 26) and
is well-established in animal models (27).
Interestingly, Tomer et al. has recently provided some
confirmatory evidence to our proposal, as they also found
that intrathymic TSHR expression was lower in individuals
homozygous for the disease-associated allele. In addition, these
authors have shown that the effect of SNPs in intron 1 on the
expression of TSHRmay depend on the differential affinity of the
allele for the PLZF transcription repressor factor. In turn, PLZF
is regulated by IFN-α (28) and it is known that there is a strong
IFN signature in the GD thyroid glands (29, 30).Moreover, IFN-α
therapy can trigger thyroid autoimmunity when administered for
hepatitis C virus infection (31). These authors propose that IFN-
α can contribute to triggering GD by reducing TSHR expression
in the thymus.
These two non-mutually exclusive mechanisms propose that
the SNPs located in intron 1 participate in the regulation of TSHR
expression through: (1) differential alternative splicing in the
thyroid; and (2) modulation of expression levels in the thymus.
To date, the effect of TSHR intron 1 polymorphisms on the
differential expression of its isoforms (ST4 and ST5) has only
been analyzed in the thyroid, in which the level of expression
is relatively high compared with the thymus. However, although
the level of TSHR expression and presumably its isoforms in the
thymus is lower, it can be critical since it is in the thymus where
the T lymphocyte repertoire is configured.
To better understand how the complex expression of TSHR in
both the thymus and thyroid canmodulate central and peripheral
tolerance to TSHR, it is useful to precisely identify the levels
of different isoform expression in these two tissues and analyze
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the influence of intron 1-associated SNPs on their expression.
The results presented here constitute a detailed analysis of TSHR
isoform expression in each tissue and provide insight into how
TSHR tolerance may fail.
MATERIALS AND METHODS
Patients and Samples
In this retrospective study, the diagnosis was made based on
thyroid hormone levels, thyroid antibodies, including TSHR
antibodies and ultrasound and scintiscan images, by experienced
endocrinologists. Thyroid tissue was obtained from 49 patients
(43 females, 7 males; age range: 15–71 years) recruited from
the Endocrinology Clinics of Hospital Universitari Germans
Trias i Pujol (HUGTiP) and Hospital Universitari Vall d’Hebron
(HUVH), both of which are affiliated with the Universitat
Autònoma de Barcelona (UAB) (Supplementary Table 1). The
samples were processed as previously described (32).
Thymic tissue was obtained from 39 patients undergoing
corrective cardiac surgery (31 pediatric and 8 adult patients;
15 females and 24 males; age range: 4 days−72 years),
from the Departments of Heart Surgery of HUGTiP or
HUVH. All samples were processed within 4 h of resection
under sterile conditions, as previously described (33)
(Supplementary Table 2).
Informed consent was obtained from all participants and the
studies have been approved by the local institutional ethics review
board of the participating institutions (ref PR AG-145/2011).
DNA and RNA Isolation
Both genomic DNA (gDNA) and total RNA were isolated from
the total thyroid and thymus tissue using standard methods
(QIAamp DNA Mini QIAcube Kit and RNeasy Mini Kit,
QIAGEN, Hilden, Germany). An additional step of DNase I
treatment was applied to the RNA samples (RNase-free DNase
set kit, QIAGEN). To check for contaminating gDNA in the RNA
samples, 100 ng of the total RNA were subjected to 45 cycles of
PCR using specific primers for a 309 nt non-transcribed region
of the CTLA4 promoter. Only samples free of DNA were used
for subsequent experiments.
Genotyping TSHR Polymorphisms
DNA from the gland donors was genotyped for the two SNPs
(rs179247 and rs12101255) known to be strongly associated with
GD and for one non-associated SNP (rs2288495), by real-time
PCR using TaqMan R© SNP genotyping assays (TaqMan R© SNP
Genotyping Assay, Applied Biosystems, UK).
Allele-Specific Quantification Using
Massive Parallel Sequencing
[Next-Generation Sequencing [NGS]]
To more precisely assess the effect of the rs179247 allele on the
overall TSHR transcription, we used massive parallel sequencing
(NGS). DNA-free RNA samples from the thyroid and thymus
were obtained as described. To preserve the pre-mRNA in the
complementary DNA (cDNA) synthesis step, retro-transcription
of the RNA samples was performed using random primers (First
Strand cDNA Synthesis Kit for RT-PCR [AMV], Roche, Basel,
Switzerland). The specific primers were designed for the TSHR
gene intron 1 region containing the rs179247 SNP (233 bp
amplimer) (Supplementary Table 3).
Library Preparation, DNA Sequencing, SNP Calling,
and Genotyping
Briefly, the target-specific primers were synthesized using
CS1/CS2 tags (Fluidigm, San Francisco, CA) followed by a
two-step PCR reaction. First, the region of interest was amplified
with target-specific tagged primers, and second, the sample-
specific barcode and adapters were introduced to generate the
sequencing library (Fluidigm). A GeneAmp R© PCR System 9700
Thermal Cycler (Applied Biosystems, Foster City, CA) was used
for the amplification. PCR products were pooled and purified
using a MinElute Gel Extraction Kit (50) (Qiagen). The pool
was run using the paired-end sequencing method on a MiSeq
sequencing system (Illumina, San Diego, CA, USA) using the
MiSeq reagent kit v2 (500 cycles) (Illumina). Finally, the FASTQ
files were analyzed for the SNP rs179247 by read mapping and
variant calling using the CLC Genomic Workbench software
version 9.5.1 (CLC Bio, Qiagen, Aarhus, Denmark). A total of 19
thymus and 8 thyroid samples from heterozygous individuals for
the SNP rs179247 were tested (Supplementary Table 4).
Quantification of the Relative Gene
Expression by qPCR
The level of gene expression for the full-length human TSHR
mRNA (flTSHR) and two TSHR alternatively spliced transcripts
(ST4 and ST5) were measured by qPCR using Taqman probes.
DNA-free RNA samples from the thyroid and thymus were
obtained as described above. The cDNA was synthesized using
Oligo(dT) primers (First Strand cDNA Synthesis Kit for RT-
PCR (AMV), Roche). To measure the level of flTSHR expression,
we used a pre-designed TaqMan R© Gene Expression Assay that
spans the TSHR exons 9 and 10 (assay ID: Hs01053841_m1).
To measure the flTSHR, ST4, and ST5 transcripts, we used
the primers and probes as described by Brand et al. (21)
(Supplementary Table 5). When checking the sequences of the
primers and probes, we realized that the ST5 probe sequence used
by Brand et al. did not coincide with the ST5 consensus sequence
by one nucleotide, and we modified the ST5 probe accordingly
(Supplementary Table 5). Reactions were run on anAbi Prism R©
7900 HT instrument (Applied Biosystems) in triplicate and the
CT average was used for further statistical analysis. The CV was
always < 15%. Normalization of the results was performed in
accordance with the relative quantification 2-11Ct method (34)
with respect to the constitutive expression of the GAPDH gene.
To display the results of the ST4 and ST5 isoform expression, we
also used the ratio to flTSHR (35).
TSHR Detection in Thymocytes and Thymic
APCs by Indirect Immunofluorescence
To investigate how TSHR is presented in the thymus,
we stained thymic 5µm cryostat sections with monoclonal
antibodies (mAbs) specific for TSHR (clone 49, Thermofisher,
Waltham, MA, USA), CD68 as a macrophage marker (clone
Y1/82A Biologend, San Diego, CA, USA), and CD11c as a
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dendritic cell marker (clone CBR-p150/4G1, Thermofisher).
To avoid cross-reactivity, the Ig isotype or species-specific
secondary labeled anti-sera were used. For each protocol,
the controls included sections incubated with the conjugated
secondary anti-sera without the corresponding primary antibody
to assess the background. Sections in which each of the
primary antibodies in the protocol were omitted to detect
any possible cross-reactions. Samples from five different glands
(1 male and four female donors; age range: 10 months
to 3 years and 7 months) were used. The sections were
first examined under a UV photomicroscope equipped with
the adequate filters and selected sections were examined
under a confocal microscope (FV1000, Olympus Corporation,
Tokyo, Japan).
Statistical Analysis
Descriptive data were presented as the mean ± standard
deviation (SD) or median and semi interquartile range (SIR).
The data were analyzed using a non-parametric test, U-Mann
Whitney test, or Kruskal-Wallis test with a multiple comparisons
correction (Dunn’s test), except for the analysis of the NGS
data, which followed a normal distribution (t-test). The accepted
p-value is <0.05. We used GraphPad Prism 5.0 program
(GraphPad Software, La Jolla CA) for the statistical analysis and
figure generation.
RESULTS
Analysis of TSHR Transcripts in the
Thymus and Thyroid
We analyzed the relative expression of full-length TSHR
(flTSHR) transcripts by qPCR and its two major alternatively
spliced transcripts (ST4 and ST5) from the cDNA of 39
and 49 samples collected from the thymus and thyroid
tissue, respectively. The level of flTSHR expression in the
thymus was higher than expected, which was ∼20% of
the expression observed in the thyroid (median thymus:
651 ± 580 vs. median thyroid: 2860 ± 1792) (Figure 2A).
Although these expression levels are similar to those mentioned
by Kim van der Weerd (36), they are higher than the
expression levels reported in several databases [e.g., BioGps
(37) or EMBL-EBI Expression Atlas [https://www.ebi.ac.uk/
gxa]]. Recently, this relatively high level of ST4 expression in
the thymus was also reported by Latif et al., who designated
it TSHR v1.3 (16).
Age was found to have an effect on TSHR expression in the
thymus. The average level of flTSHR expression in donors aged 0
to 11 years-old was 1,135 ± 1,110 and from donors ages 40 to 80
years old was 436± 657 (p< 0.05) (Figure 2B). Since our thymus
samples were from relatively young patients, this may explain the
discrepancy with levels recorded in the databases.
It is of interest that the relative levels of flTSHR and
ST4 expression were not as different as expected in the
thymus and thyroid and they were higher for flTSHR than
for ST4 (thyroid flTSHR 2,860 ± 1,792, ST4 2,135 ± 961,
ratio flTSHR/ST4 = 1.34; thymus flTSHR 651 ± 580, ST4
337 ± 299, ratio flTSHR/ST4 = 1.93). In contrast, the
level of isoform ST5 expression was substantially lower in
both tissues (thyroid ST5 303 ± 104 and thymus ST5
15 ± 8). Interestingly, the level of ST5 expression was
proportionally much lower in the thymus compared with
the thyroid (ST5 represents 6% compared to 1.5% of the
total transcripts (flTSHR+ ST4 + ST5) in the thyroid and
thymus, respectively) (Figure 2A). This difference is also
FIGURE 2 | Gene expression of the TSHR isoforms in the thymus and thyroid. (A) mRNA expression of the full-length TSHR (flTSHR) and its isoforms (ST4 and ST5)
in the thymus and thyroid. The relative level of mRNA expression was measured using quantitative PCR of the cDNA from 49 thyroid and 39 thymus samples. Each
sample was tested in triplicate and the standard deviation was always <15% of the mean value. Values were normalized to GAPDH expression using the comparative
CT method and expressed as copies per 100,000 copies of GAPDH. Each point represents the mean value of triplicate results from one sample. The median ± IQR of
each group is shown. ***p < 0.0001, Kruskal Wallis test with a Dunn’s multiple comparison test. (B) The relative mRNA expression of flTSHR in the thymus samples
was stratified into pediatric (0–11 years; n = 31) and adults (40–80 years; n = 8) samples. The mean ± SEM of each group is shown. *p < 0.05 using a t-test for
independent samples.
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FIGURE 3 | Proportionally lower expression of the TSHR ST5 isoform in the thymus compared with the thyroid. The expression ratios of ST5 with flTSHR (A) and ST4
(B) in the thymus and thyroid were calculated. Each point represents the mean value of triplicate results from one sample. The median ± IQR of each group is shown.
***p < 0.0001 using a t-test for independent samples.
reflected when comparing the ratios of ST5 expression with
flTSHR or ST4 in both tissues (thyroid flTSHR/ST5 = 9.86
vs. thymus flTSHR/ST5 = 39.01; p < 0.0001) (Figure 3A)
(thyroid ST4/ST5 = 4.5 vs. thymus ST4/ST5 = 24.3; p <
0.0001) (Figure 3B).
The above results indicate that substantial soluble TSHR likely
exists within the thymus, which is primarily derived from the
transcription of ST4. Thus, this expressionmay have implications
for establishing central TSHR tolerance.
NGS Confirms the Thymus-Specific
Influence of TSHR Expression by
GD-Associated SNPs
We previously demonstrated that the risk allele, rs179247 (one
of the main TSHR GD-associated SNPs), determined lower
TSHR expression in the thymus but not in the thyroid (38).
However, since we used a semiquantitative technique (allele-
specific transcript quantification by qPCR using FRET probes),
we decided to apply massive parallel sequencing, which is a
more reliable quantitative technique, for the comparison of
rs179247 TSHR allele expression in heterozygous individuals. It
should be emphasized that since rs179247 is located in intron
1, we took care in obtaining the cDNA from the pre-mRNA
(immature RNA before the splicing process). The designed
primers do not discriminate between cDNA and gDNA and
consequently, the contaminating gDNAmust be absent to obtain
reliable results.
Allele-specific quantification was measured in the gDNA
and the cDNA from 19 thymus and 8 thyroid samples from
heterozygous donors (previously genotyped for rs179247). We
obtained good coverage, with a mean depth in the gDNA samples
of 27,000× (i.e., 27,000 sequences or “reads” interrogating the
rs179247 position) and 9,000× in the cDNA samples, with no
significant differences between the thymus and thyroid samples
(Table 1). The results showed that the ratio between the G
(protecting) and the A (predisposing) alleles for gDNA was
TABLE 1 | Allele-specific transcript quantification by NGS.
Sample
type
Depth of
coveragea
Balanceb Counts
(G allele)
Frequency
(G allele) %
THYROID
102 gDNA 29548x 0.49 15,054 50.95
cDNA 9305x 0.49 4,926 52.94
218 gDNA 25800x 0.49 13,283 51.48
cDNA 5006x 0.49 2,746 54.85
355 gDNA 15027x 0.49 7,771 51.71
cDNA 9200x 0.50 4,940 53.70
381 gDNA 25044x 0.49 12,633 50.44
cDNA 23579x 0.49 12,361 52.42
409 gDNA 25049x 0.50 12,726 50.80
cDNA 14221x 0.49 7,211 50.71
430 gDNA 29863x 0.49 15,038 50.36
cDNA 1693x 0.49 764 45.13
452 gDNA 32564x 0.49 16,484 50.62
cDNA 1738x 0.50 877 50.46
92 gDNA 20911x 0.49 10,717 51.25
cDNA 13439x 0.49 6,916 51.46
THYMUS
101 gDNA 28664 0.49 14,453 50.42
cDNA 6933 0.49 3,960 57.12
117 gDNA 35762 0.49 18,282 51.12
cDNA 5912 0.49 3,764 63.67
119 gDNA 24245 0.49 12,165 50.18
cDNA 4570 0.49 2,663 58.27
126 gDNA 28552 0.50 14,280 50.01
cDNA 4510 0.49 2,481 55.01
(Continued)
Frontiers in Immunology | www.frontiersin.org 6 July 2019 | Volume 10 | Article 1695
Marín-Sánchez et al. TSHR Isoforms and Tolerance
TABLE 1 | Continued
Sample
type
Depth of
coveragea
Balanceb Counts
(G allele)
Frequency
(G allele) %
145 gDNA 33290 0.50 16,932 50.86
cDNA 17575 0.49 9,996 56.88
159 gDNA 25178 0.50 12,664 50.30
cDNA 6616 0.49 4,299 64.98
16 gDNA 22447 0.49 11,221 49.99
cDNA 13429 0.49 8,649 64.41
171 gDNA 30800 0.49 15,640 50.78
cDNA 4138 0.49 2,438 58.92
188 gDNA 29066 0.49 14,720 50.64
cDNA 342 0.48 185 54.09
195 gDNA 31457 0.49 16,255 51.67
cDNA 3656 0.50 2,235 61.13
197 gDNA 31543 0.49 16,169 51.26
cDNA 8058 0.49 4,385 54.42
225 gDNA 26017 0.49 13,152 50.55
cDNA 18406 0.49 11,164 60.65
229 gDNA 31049 0.50 15,955 51.39
cDNA 7373 0.50 4,392 59.57
235 gDNA 31949 0.49 16,325 51.10
cDNA 14662 0.49 8,516 58.08
263 gDNA 33124 0.49 16,852 50.88
cDNA 16402 0.49 9,478 57.79
28 gDNA 27355 0.49 13,931 50.93
cDNA 6143 0.49 3,593 58.49
38 gDNA 4047 0.49 2,110 52.14
cDNA 6701 0.50 4,253 63.47
4 gDNA 25273 0.49 12,879 50.96
cDNA 16769 0.49 9,802 58.45
72 gDNA 31112 0.49 15,957 51.29
cDNA 7426 0.49 4,277 57.59
Results of cDNA samples are indicated in bold.
aThe number of unique reads (i.e., sequences) which interrogate the position of rs179247.
bBalance between reads from the forward or reverse primer. A value of 0.5 indicates that
half of the reads come from each primer (i.e., there is no strand bias).
always 1 in both the thyroid and thymus, reflecting the existence
of the same number of maternal and paternal DNA copies in
each cell (Figure 4; Table 1). For cDNA, the percentage of reads
corresponding to the G allele in the thyroid was ∼50% (range:
45.1–54.8%) with a G/A allele ratio of 1± 0.1 SD. In contrast, the
G/A allele ratio in the thymus was 1.5 ± 0.2 SD, with a mean of
59.1% (ranging: 54.1–65%). These findings indicate that there is
unbalanced allele transcription only in the thymus (reflecting a
tissue-specific effect) and demonstrates that the protective TSHR
G allele is preferentially transcribed.
FIGURE 4 | Preferential transcription of the rs179247 GD protective allele in
the thymus. We used massive parallel sequencing to determine the relative
abundance of TSHR alleles in 19 thymus and 8 thyroid cDNA samples from
individuals heterozygous for the GD-associated SNP, rs179247. Specific
primers were designed for the intron 1 region of the TSHR gene containing the
analyzed SNP. Allele-specific quantification was measured in the gDNA, as a
control for equal biallelic representation, and the cDNA in all samples. Each
point represents the ratio between the G (protecting) and the A (predisposing)
allele reads. ***p < 0.001 using a Kruskal Wallis test with Dunn’s multiple
comparison test.
GD-Associated Intron 1 SNPs Do Not
Influence Alternative TSHR Splicing in the
Thyroid and Thymus
To assess the effect of intron 1 GD-associated SNPs on the
differential transcription of alternatively spliced TSHR isoforms,
gDNA samples from donors (n = 88, 49 thyroid and 39 thymus
donors) were genotyped for the rs179247 and rs12101255 SNPs
associated with GD, and for the control SNP, rs2288495 (located
in the 3’ UTR of TSHR, not in linkage disequilibrium with
rs179247; r = 0.05) (21, 38). The relative level of flTSHR, ST4,
and ST5 expression was measured in the thymus and thyroid by
qPCR and normalized to the level of GAPDH expression. The
ratio of each of the truncated ST4 and ST5 transcripts to flTSHR
was calculated for each individual and the data were grouped by
SNP genotype (Figure 5).
In the thyroid samples, there was no overall significant
effect of the genotypes on ST4 or ST5 expression, either
normalized to GAPDH or expressed as a ratio to flTSHR
(Figures 5A–F). Specifically, there were no statistically
significant differences between the protective (GG for rs179247
and CC for rs12101255) and the predisposing genotypes
(AA for rs179247 and TT for rs12101255). These results
differ from those reported by Brand et al. in their original
publication (21).
In the analysis of the relative expression of the ST4
and ST5 transcripts in the thymic samples, there is no
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FIGURE 5 | Effect of GD-associated SNPs (rs179247 and rs12101255) on the expression of TSHR alternatively spliced isoforms in human thyroid and thymus
samples. The relative level of flTSHR, ST4, and ST5 expression was measured by qPCR and normalized to the level of GAPDH expression. The ratio of each short
ST4 and ST5 transcript to the flTSHR was calculated for each individual and the data were grouped by SNP genotype. (A–F) The relative ST4 and ST5 expression in
the thyroid is presented. (G–L) Relative level of ST4 and ST5 expression in the thymus is presented. A non-GD-associated SNP (rs2288495) was also included as a
control. Each point represents the mean value of triplicate results from one sample. The mean ± SEM of each group is shown. A Kruskal-Wallis with Dunn’s multiple
comparison test was used.
overall significant effect of the genotypes for ST4 or ST5
expression relative to flTSHR (Figures 5G–L). There are no
statistically significant differences between the protective and the
predisposing genotypes. In both the thymus and thyroid, the
control SNP was not associated with GD (rs2288495), but was
also not significantly different.
In addition to the codominant and the most likely recessive
models considered above, we have also considered the dominant
model for the rs179247G and rs21201255C alleles; however,
no statistical differences were found for either of these models
(Supplementary Figure 1).
TSHR Is Associated With Both
Thymocytes, Macrophages, and Dendritic
Cells in the Thymus
It would be extremely interesting to elucidate how TSHR
and its isoforms are processed and presented in the thymus,
as this should determine the level of central tolerance and
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FIGURE 6 | TSHR protein expression in the thymus detected by immunofluorescence. Abundant cells in the cortex that can be morphologically identified as
thymocytes and other larger cells (left bottom panel) are positive for TSHR visualized in the green channel. The bottom-right pictures combine the macrophage marker,
CD68, and the dendritic cell marker, CD11c, reveal some orange-yellow cells that correspond to macrophages that contain TSHR. There are also some violet cells
(probably DCs), for which is more difficult to identify TSHR staining but some cytoplasmic light blue fluorescence (from the overlapping of dark blue and green), is
observed. The arrow points to a macrophage visible in all micrographs except the CD11c staining, and the arrowhead points to a dendritic cell visible in all
micrographs except in the CD68 staining.
more specifically, which epitopes escape this central tolerance.
Since there are no TSHR isoform-specific antibodies available,
after testing several reagents, we finally selected a mAb that
resulted in clear staining in the thyroid and low background
in the lymphoid tissue (Supplementary Figure 2). As seen in
Figure 6, the thymocytes located in the inner cortical areas of
the thymus are clearly stained for TSHR. Interestingly, some
positive dots were observed, indicative of small quantities of
TSHR associated with both CD68+ macrophages and CD11c+
dendritic cells.
DISCUSSION
In this article, we report three significant findings: (1) relatively
high expression of the short ST4 and ST5 TSHR transcripts was
observed in the thymus, which may have implications for the
establishment of central TSHR tolerance; (2) massive parallel
sequencing was used to definitively correlate the differential effect
of GD-associated rs179247 SNP alleles on TSHR transcription
in the thymus but not in the thyroid; and (3) there was an
absence of an effect of GD-associated SNPs (rs179247 and
rs12101255) in modulating mRNA splicing in the thyroid and
thymus, resulting in similar levels of ST4 and ST5 transcripts
between samples from individuals homozygous for the risk or
protective genotype.
This is the first study to simultaneously address the two
mechanisms proposed to explain the functional role of TSHR
intron 1 GD-associated SNPs. The mechanism, which involves
defective central tolerance, was initially proposed by our group.
In our previous study, we showed that individuals with the
rs179247 GD-protective genotype displayed higher levels of
thymic TSHR expression than those with the disease-associated
genotype (38). This finding has been also later reported by
Yaron Tomer’s group (28). In both studies, the results were
obtained measuring gene expression by qPCR in genotyped
individuals; however, since this approach is vulnerable to
individual confounding factors that can influence the results
(e.g., individual genetic background, age, and sex differences),
we used an allele-specific quantification (ASQ) method to
quantify the contribution of each allele (risk vs. protective)
in heterozygous individuals. This ASQ method was a qPCR-
based semiquantitative technique and confirmed higher levels
of protective allele expression in the thymus (38). In the
present study, we aimed to definitely corroborate these results
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using a more robust quantitative technique of massive parallel
sequencing (NGS). The high on-target coverage that was
obtained (>9,000 reads in cDNA samples) allowed us to precisely
quantify the number of transcripts expressed from each allele in
heterozygous individuals. We confirmed the unbalanced tissue-
specific transcription of the two alleles with the observation
that the GD-protective allele was expressed 1.5-fold more on
average, compared to the GD-predisposing allele in the thymus,
but not in the thyroid. Although it remains unclear how these
moderate differences in the expression of a self-antigen in the
thymus have such an important effect on establishing the level
of central tolerance, they may be related to the limited window
of opportunity that maturing thymocytes have to interact with
tissue-restricted antigens in the thymus (39). The magnitude of
this imbalance here reported by NGS is in the same order of
magnitude of that detected by ourselves using ASQ by qPCR
(38), and of that reported by Pugliese et al. and Vafiadis et
al. for the insulin gene in the first publications describing this
phenomenon (25, 40).
The second mechanism used to explain the functional role of
TSHR intron 1 GD-associated SNPs was proposed by Brand et
al. and highlighted the differential regulation of mRNA splicing
by these SNPs. The authors showed that GD-risk alleles of
intron 1 SNPs (rs179247 and rs12101255) were associated with
a relative increase in ST4 and ST5 expression, which would result
in a higher production of variants encoding putatively more
antigenic soluble TSHR isoforms (21). In our study, when we
attempted to replicate this experiment, rs179247 and rs12101255
did not affect the transcription of the ST4 and ST5 isoforms
in the thyroid or thymus. Although these results differ with
those reported by Brand et al. for an unknown reason, this
discrepancy may be the result of our study involving a much
larger series of thyroid samples. We used 49 thyroid samples
compared with the 12 samples used by Brand et al. In their
study, when the 12 samples were divided by genotype, the result
was small groups consisting of only three to five samples each
(one of which had a high dispersion of the values), which the
authors stated required further confirmation (21). Additionally,
the ST5 probe sequence described in Brand et al. had an incorrect
nucleotide when compared with the current reference genome.
Furthermore, it is difficult to predict if this mismatch had an
effect on ST5 quantification.
We believe that our results are robust due to the use of highly
reliable and quantitative methods (NGS for ASQ and probe-
specific qPCR for gene expression). The age, clinical conditions,
and presence of thyroid autoantibodies in the donors had no
effect on the results, and they were excluded as confounding
factors (data not shown). Therefore, we can conclude that
TSHR intron 1 GD-linked SNPs are associated with different
levels of thymic TSHR expression, but not with differential
mRNA splicing.
Perhaps the most striking finding in the present study is
the demonstration of high levels of short TSHR transcript
expression, especially ST4, in the thymus [recently confirmed
by Latif et al. (16)]. This is relevant if we consider the peculiar
distribution of TSHR expression within the thymus. Different
from most other restricted tissue antigens (RTAs), while the
TSHR receptor is only minimally expressed by medullary thymic
epithelial cells (mTECs), it is expressed at relatively high levels
by double positive thymocytes themselves, for which it appears
to play a role in maturation and differentiation (9, 36, 38, 41).
Therefore, it should be assumed that there are two sources of
TSHR protein in the thymus: (1) the TSHR anchored in the
thymocyte membrane and the soluble ST4 and ST5 isoforms
generated by alternative splicing.We and others consider that the
ST4 and ST5 isoforms are translated (ST4 and ST5 mRNA have
all the features of mature transcripts), even if no experimental
evidence is available. According to the transcript levels, soluble
short TSHR isoforms may be present at levels comparable to
that of membrane-anchored TSHR. It would be important to
determine which of these two forms (soluble vs. membrane-
anchored) play the main role in the establishment of central
tolerance to TSHR. It is difficult to answer to this question
with certainty given the present data and reagents. As previously
shown by van der Weerd (36) and ourselves (41), as well as by
our IFL experiments in this paper, TSHR is mainly expressed in
double positive thymocytes; however, low levels are also observed
in both macrophages and dendritic cells. There are currently no
reagents that can be used to identify the isoforms detected by IFLs
in these APCs. Massive quantities of double positive thymocytes
die by apoptosis in the thymus cortical compartment. It is known
that they are disposed by macrophages that ingest apoptotic cells.
Importantly, macrophages are much less efficient than mTEC or
thymic dendritic cells at inducing tolerance to self-autoantigens,
which should apply to thymocyte antigens (42, 43). In contrast,
soluble TSHR isoforms are likely engaged by thymic dendritic
cells, which are highly efficient at inducing negative selection.
If central tolerance to TSHR is predominantly dependent on
the two soluble ST4 and ST5 isoforms, the C terminal segment
consisting of 533 aa out of the 764 aa of the full length TSHR
molecule would not be subjected to the tolerization process. In
GD, although the pathogenic stimulating antibodies are directed
at the N terminal LRR in the ectodomain, tolerance is ultimately
dependent on T cells. Thus, B cells that recognize the ectodomain
may receive help from T cells that recognize epitopes in the long
C terminal stretch of TSHR, to which tolerance is incomplete.
This is an important issue because a demonstrated mechanism
of central tolerance failure is the expression of different protein
isoforms in both the thymus and periphery. This was first
demonstrated by Klein and Kyewski in experimental acute
encephalomyelitis induced by the myelin proteolipid protein in
SJL/J mice (44). Since this original description, similar results
have also been demonstrated for the islet antigen, I-A2 (45),
and is also used to explain autoantibodies to post-translationally
modified proteins (e.g., citrullinated peptides in rheumatoid
arthritis) (46). In addition, the role of TSHR expression in the
thymus for protection against the development of pathogenic
anti-TSHR antibodies has recently been demonstrated in amouse
model (47). Therefore, we propose that a crucial mechanism
for the failure of TSHR tolerance is the lack of presentation
of the full-length TSHR molecule by tolerogenic APCs in the
thymic medulla.
Collectively, the results of the present study support
the functional role of TSHR intron 1 GD-associated SNPs
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in modulating central tolerance through influencing the
intrathymic expression of TSHR. In addition, these findings
provide a novel explanation as to why the loss of tolerance
to TSHR occurs with relatively high frequency (i.e., differential
expression of isoforms in the thymus vs. thyroid). Furthermore,
a deeper analysis of the differential isoform expression (i.e.,
measurements of the corresponding proteins, the presence of
TSHR peptides in the thymic ligandome) and epitope specificity
of TSHR-specific autoreactive T cells should be assessed in
future studies.
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